Ann: Appendix 4E & Annual Report 2019, page-6

In light chain amyloidosis, "A PCT patent application has entered National Phase and awaits examination", (1 July, 2016). PCT application is the gateway to patents in over 100 countries. Most likely ATH has already selected where to apply. The paper was published only in September 2017, clearly after the patent application. This application is now public IMO.
Nothing yet about "reversing antibiotic resistance" at this phase but IMO if an application has been done it would be a secret, likely totally for 18 months. Unfortunately the publication was done too early, most likely before a patent application. I would think that a good patent agent could solve this problem (perhaps there is 6 months limit?). So it could take still a year before we will get any info about this (???). But unfortunately there is nothing listed in this annual report.